by Richard Daverman, PhD
June 20, 2012 -- Xiamen Innovax Biotech expects to launch Hecolin, its hepatitis E vaccine, in China later this year. It will form partnerships to bring the product to worldwide markets. In January of this year, the SFDA approved the vaccine after it was effective in a large Phase III trial. Innovax is the development arm of the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University. More details....
